Minimum Inhibitory Concentrations before and after Antibacterial Treatment in Patients with Mycobacterium abscessus Pulmonary Disease

Abstract

The MICs of isolates from 86 patients with Mycobacterium abscessus (MABS); 46 with Mycobacterium abscessus subsp. abscessus (Mab), and 40 with Mycobacterium abscessus subsp. massiliense (Mma) were retrospectively analyzed. The main findings are as follows: i) Mma were significantly more susceptible to clarithromycin and azithromycin than Mab, and both subspecies tended to be more susceptible to clarithromycin than azithromycin. ii) Most isolates were susceptible to amikacin (93.0%), and over half to linezolid (55.8%). iii) Fifty-one isolates (59.3%) had MIC values of less than 1 μg/mL for sitafloxacin, and 65 (75.6%) had less than 0.5 μg/mL for clofazimine, which seems worth clinical investigating. iv) Among nine cases analyzed chronological changes, only two patients showed obvious MIC result changes even after the long-term multidrug treatment.

The in vitro effect of new combinations of carbapenem–β-lactamase inhibitors for Mycobacterium abscessus

“…Regarding colony morphology, there was a tendency of lower tebipenem MICs for rough compared to smooth morphology (MIC50 128 vs 256 mg/L); however, this was not statistically significant ( P = 0.064). Otherwise, there were no significant differences in MIC50s for any of the carbapenem alone or in combination with BLI with regard to (a) MABC subspecies, (b) erm genotype, (c) formation of cording, or (d) morphology (see https://doi.org/10.6084/m9.figshare.23589786.v1 ), which is in line with previous research ( 23 – 28 ). From our data, a rough colony morphology does not appear to be a major mechanism of resistance to carbapenems ( 9 ).…”

In Vitro Antimicrobial Activities of Tigecycline, Eravacycline, Omadacycline, and Sarecycline against Rapidly Growing Mycobacteria

“…massiliense , and M. fortuitum of 0.25 μg/mL, 0.25 μg/mL, and 0.0625 μg/mL, respectively. This in vitro activity of ERC was equivalent to or even better than that of clarithromycin, which is the core antimicrobial in the M. abscessus complex treatment regimen, with MICs ranging between 0.0625 and 2 μg/mL for susceptible strains ( 32 ). Pharmacokinetic (PK) studies have demonstrated that the maximum concentration ( C max ) values of ERC following intravenous administration at doses ranging from 0.5 to 1.5 mg/kg were in the range of 1.8 μg/mL to 3.4 μg/mL ( 33 , 34 ).…”

Non-tuberculous mycobacterial disease: progress and advances in the development of novel candidate and repurposed drugs

“…massiliense , and M. fortuitum (1 μg/mL, 1 μg/mL, and 0.25 μg/mL versus 1 μg/mL, 2 μg/mL, and 2 μg/mL) ( Zhang et al., 2023 ). Furthermore, the in vitro antimycobacterial activity of ERC was similar to or better than that of CLA (MIC: 0.0625–2 μg/mL for susceptible strains), with CLA being the core antimycobacterial in the Mab treatment regimen ( Fujiwara et al., 2021 ).…”